Loading...
Loading...
SABSW| Name | Value |
|---|---|
| Revenues | 0.9M |
| Cost of Revenue | 2.0M |
| Gross Profit | -1.0M |
| Operating Expense | 10.4M |
| Operating I/L | -11.4M |
| Other Income/Expense | 6.4M |
| Interest Income | 0.5M |
| Pretax | -5.0M |
| Income Tax Expense | -13.4M |
| Net Income/Loss | -5.0M |
SAB Biotherapeutics, Inc. is a biopharmaceutical company specializing in the development of immunotherapies for infectious diseases, autoimmune diseases, and oncology. The company generates revenue through the development and commercialization of its immunotherapy products, including SAB-142 for Type 1 diabetes, SAB-176 for seasonal influenza, and SAB-301 for Middle East Respiratory Syndrome Coronavirus (MERS-COV). These products are designed to address critical medical needs and have the potential to contribute to the company's financial success.
